171 related articles for article (PubMed ID: 28027027)
1. Estimating State Transitions for Opioid Use Disorders.
Krebs E; Min JE; Evans E; Li L; Liu L; Huang D; Urada D; Kerr T; Hser YI; Nosyk B
Med Decis Making; 2017 Jul; 37(5):483-497. PubMed ID: 28027027
[TBL] [Abstract][Full Text] [Related]
2. The costs of crime during and after publicly funded treatment for opioid use disorders: a population-level study for the state of California.
Krebs E; Urada D; Evans E; Huang D; Hser YI; Nosyk B
Addiction; 2017 May; 112(5):838-851. PubMed ID: 27981691
[TBL] [Abstract][Full Text] [Related]
3. Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: A natural history study.
Carlson RG; Nahhas RW; Martins SS; Daniulaityte R
Drug Alcohol Depend; 2016 Mar; 160():127-34. PubMed ID: 26785634
[TBL] [Abstract][Full Text] [Related]
4. Short term health-related quality of life improvement during opioid agonist treatment.
Nosyk B; Bray JW; Wittenberg E; Aden B; Eggman AA; Weiss RD; Potter J; Ang A; Hser YI; Ling W; Schackman BR
Drug Alcohol Depend; 2015 Dec; 157():121-8. PubMed ID: 26511766
[TBL] [Abstract][Full Text] [Related]
5. Characterizing longitudinal health state transitions among heroin, cocaine, and methamphetamine users.
Nosyk B; Li L; Evans E; Huang D; Min J; Kerr T; Brecht ML; Hser YI
Drug Alcohol Depend; 2014 Jul; 140():69-77. PubMed ID: 24837584
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics of treatment-seeking prescription opioid vs. heroin-using adolescents with opioid use disorder.
Subramaniam GA; Stitzer MA
Drug Alcohol Depend; 2009 Apr; 101(1-2):13-9. PubMed ID: 19081205
[TBL] [Abstract][Full Text] [Related]
7. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.
Krawczyk N; Mojtabai R; Stuart EA; Fingerhood M; Agus D; Lyons BC; Weiner JP; Saloner B
Addiction; 2020 Sep; 115(9):1683-1694. PubMed ID: 32096302
[TBL] [Abstract][Full Text] [Related]
8. The association of criminal justice supervision setting with overdose mortality: a longitudinal cohort study.
Binswanger IA; Nguyen AP; Morenoff JD; Xu S; Harding DJ
Addiction; 2020 Dec; 115(12):2329-2338. PubMed ID: 32267585
[TBL] [Abstract][Full Text] [Related]
9. Buprenorphine pharmacotherapy and behavioral treatment: comparison of outcomes among prescription opioid users, heroin users and combination users.
Nielsen S; Hillhouse M; Mooney L; Ang A; Ling W
J Subst Abuse Treat; 2015 Jan; 48(1):70-6. PubMed ID: 25065489
[TBL] [Abstract][Full Text] [Related]
10. Racial/Ethnic Differences in Prevalence Trends for Heroin use and Non-Medical use of Prescription Opioids Among Entrants to Opioid Treatment Programs, 2005-2016.
Pouget ER; Fong C; Rosenblum A
Subst Use Misuse; 2018 Jan; 53(2):290-300. PubMed ID: 28854060
[TBL] [Abstract][Full Text] [Related]
11. Impact of prerelease methadone on mortality among people with HIV and opioid use disorder after prison release: results from a randomized and participant choice open-label trial in Malaysia.
Bazazi AR; Culbert GJ; Wegman MP; Heimer R; Kamarulzaman A; Altice FL
BMC Infect Dis; 2022 Nov; 22(1):837. PubMed ID: 36368939
[TBL] [Abstract][Full Text] [Related]
12. Retention in methadone maintenance drug treatment for prescription-type opioid primary users compared to heroin users.
Banta-Green CJ; Maynard C; Koepsell TD; Wells EA; Donovan DM
Addiction; 2009 May; 104(5):775-83. PubMed ID: 19344438
[TBL] [Abstract][Full Text] [Related]
13. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B
PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578
[TBL] [Abstract][Full Text] [Related]
14. Prevalence, Diagnosis, and Treatment Rates of Mood Disorders among Opioid Users under Criminal Justice Supervision.
Mbaba M; Brown SE; Wooditch A; Kiss M; Murphy A; Kumari S; Taxman F; Altice F; Lawson WB; Springer SA
Subst Use Misuse; 2018 Jul; 53(9):1519-1528. PubMed ID: 29333954
[TBL] [Abstract][Full Text] [Related]
15. Opioid Agonist Treatment Recipients within Criminal Justice-Involved Populations.
Guastaferro WP; Koetzle D; Lutgen-Nieves L; Teasdale B
Subst Use Misuse; 2022; 57(5):698-707. PubMed ID: 35172673
[No Abstract] [Full Text] [Related]
16. Interventions for incarcerated adults with opioid use disorder in the United States: A systematic review with a focus on social determinants of health.
Sugarman OK; Bachhuber MA; Wennerstrom A; Bruno T; Springgate BF
PLoS One; 2020; 15(1):e0227968. PubMed ID: 31961908
[TBL] [Abstract][Full Text] [Related]
17. Comparing buprenorphine induction experience with heroin and prescription opioid users.
Nielsen S; Hillhouse M; Mooney L; Fahey J; Ling W
J Subst Abuse Treat; 2012 Oct; 43(3):285-90. PubMed ID: 22301084
[TBL] [Abstract][Full Text] [Related]
18. How many people in Canada use prescription opioids non-medically in general and street drug using populations?
Popova S; Patra J; Mohapatra S; Fischer B; Rehm J
Can J Public Health; 2009; 100(2):104-8. PubMed ID: 19839284
[TBL] [Abstract][Full Text] [Related]
19. Demographic and Clinical Correlates of Treatment Completion among Older Adults with Heroin and Prescription Opioid Use Disorders.
Choi NG; DiNitto DM; Marti CN; Choi BY
J Psychoactive Drugs; 2022; 54(5):440-451. PubMed ID: 34818983
[TBL] [Abstract][Full Text] [Related]
20. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users.
Tsui JI; Evans JL; Lum PJ; Hahn JA; Page K
JAMA Intern Med; 2014 Dec; 174(12):1974-81. PubMed ID: 25347412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
